4/17
08:10 am
evax
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 [Yahoo! Finance]
Medium
Report
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 [Yahoo! Finance]
4/17
08:00 am
evax
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Low
Report
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
4/3
09:29 am
evax
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
4/3
08:08 am
evax
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Medium
Report
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
4/2
11:37 am
evax
Evaxion Biotech A/S (NASDAQ: EVAX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
Medium
Report
Evaxion Biotech A/S (NASDAQ: EVAX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
4/2
07:23 am
evax
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection [Yahoo! Finance]
Medium
Report
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection [Yahoo! Finance]
4/2
07:00 am
evax
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
High
Report
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
3/27
07:30 am
evax
Evaxion Announces Business Update and Full Year 2023 Financial Results
High
Report
Evaxion Announces Business Update and Full Year 2023 Financial Results
3/22
07:44 am
evax
When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit? [Yahoo! Finance]
Neutral
Report
When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit? [Yahoo! Finance]
3/20
08:08 am
evax
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
3/19
07:39 am
evax
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform [Yahoo! Finance]
Medium
Report
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform [Yahoo! Finance]
3/19
07:30 am
evax
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
Low
Report
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
2/29
07:42 am
evax
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations [Yahoo! Finance]
Medium
Report
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations [Yahoo! Finance]
2/29
07:30 am
evax
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
Medium
Report
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
2/20
07:30 am
evax
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
Medium
Report
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
2/12
07:07 am
evax
Evaxion Biotech A/S (NASDAQ: EVAX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $14.00 price target on the stock.
Neutral
Report
Evaxion Biotech A/S (NASDAQ: EVAX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $14.00 price target on the stock.
2/7
08:30 am
evax
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
Low
Report
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
2/6
08:46 am
evax
Evaxion Announces Closing of $15 Million Public Offering [Yahoo! Finance]
Medium
Report
Evaxion Announces Closing of $15 Million Public Offering [Yahoo! Finance]
2/6
08:30 am
evax
Evaxion Announces Closing of $15 Million Public Offering
Medium
Report
Evaxion Announces Closing of $15 Million Public Offering
2/1
09:30 am
evax
Evaxion Biotech Announces Pricing of $15 Million Public Offering [Yahoo! Finance]
Medium
Report
Evaxion Biotech Announces Pricing of $15 Million Public Offering [Yahoo! Finance]
2/1
09:20 am
evax
Evaxion Biotech Announces Pricing of $15 Million Public Offering
High
Report
Evaxion Biotech Announces Pricing of $15 Million Public Offering
1/26
09:23 am
evax
TCBP and PCSA among pre-market losers [Seeking Alpha]
High
Report
TCBP and PCSA among pre-market losers [Seeking Alpha]